GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » Net Income

Acotec Scientific Holdings (HKSE:06669) Net Income : HK$15.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Acotec Scientific Holdings's Net Income for the six months ended in Dec. 2023 was HK$-8.6 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$15.8 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Acotec Scientific Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-0.03.


Acotec Scientific Holdings Net Income Historical Data

The historical data trend for Acotec Scientific Holdings's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings Net Income Chart

Acotec Scientific Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
25.71 -51.97 -96.83 78.33 15.85

Acotec Scientific Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only -81.48 36.45 43.60 24.47 -8.62

Acotec Scientific Holdings Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Acotec Scientific Holdings's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=15.807+0.038+0+0.00099999999999945
=15.8

Acotec Scientific Holdings's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-8.64+0.019+0+0
=-8.6

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$15.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acotec Scientific Holdings  (HKSE:06669) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Acotec Scientific Holdings's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Acotec Scientific Holdings Net Income Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Acotec Scientific Holdings (HKSE:06669) Business Description

Traded in Other Exchanges
Address
16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN
Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.
Executives
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Nexus Partners Group Limited 2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited 2101 Beneficial owner
Li Jing 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p. 2201 Interest of corporation controlled by you
Cpe Funds Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited 2101 Beneficial owner
Cpe Holdings Limited 2201 Interest of corporation controlled by you
Cpe Holdings International Limited 2201 Interest of corporation controlled by you
Cpe Gof Gp Limited 2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p. 2201 Interest of corporation controlled by you
Boston Scientific Corporation 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings (HKSE:06669) Headlines

No Headlines